The Dilemma of Whether to Release Genetic Information
By Xavier Symons,
BioEdge
| 03. 01. 2014
New studies are suggesting that doctors need to be more cautious when they release genetic information to patients.
A recent article in the American Journal of Psychiatry has examined the effects of informing patients of genetic predispositions to disease on their subsequent cognitive performance. The authors of the article, from the University of Indiana and UC San Diego, found that respondents who were informed of a disposition to Alzheimer’s performed worse on memory tests and had reduced confidence in the current power of their memory.
In the study, which involved almost 150 participants, some of the patients were given the results of genetic test for Alzheimer’s predisposition, whilst others were tested but not told of their results.
The researchers found that those participants who were informed of their predisposition to Alzheimer’s performed far worse on the tests for objective and subjective memory. The ”informed” participants showed poorer comprehension when asked to recount narratives and recall images. In subjective memory tests they were far more pessimistic about the strength of their current memory.
In addition avoiding the negative psychological effects of...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...